Age (years), mean ± SD (range) |
68.3 ± 2.8 (39-87) |
Sex, male, n (%) |
8 (32.0) |
BMI (kg/m2), median (IQR) |
19.0 ± 2.8 |
ECOG PS, n (%) |
|
4 |
3 (12.0) |
3 |
14 (56.0) |
2 |
5 (20.0) |
1 |
3 (12.0) |
0 |
0 (0.0) |
Primary cancer site, n (%) |
|
Colon |
5 (20.0) |
Pancreas |
4 (16.0) |
Breast |
3 (12.0) |
Uterine |
3 (12.0) |
Bone |
2 (8.0) |
Lung |
2 (8.0) |
Others |
6 (24.0) |
Metastases, n (%) (including duplicate answers) |
|
Lung |
11 (44.0) |
Bone |
9 (36.0) |
Liver |
9 (36.0) |
Lymph node |
5 (20.0) |
Peritoneal |
4 (16.0) |
Muscle |
3 (12.0) |
Brain |
2 (8.0) |
Pancreas |
2 (8.0) |
Subcutaneous tissue |
2 (8.0) |
Others |
8 (32.0) |
None |
1 (4.0) |
Type of pain, n (%) (including duplicate answers) |
|
Somatic pain |
17 (68.0) |
Visceral pain |
13 (52.0) |
Neuropathic pain |
21 (84.0) |
Opioids before switching to methadone, n (%) |
|
Fentanyl |
8 (32.0) |
Oxycodone |
8 (32.0) |
Tapentadol |
5 (20.0) |
Morphine |
2 (8.0) |
Tramadol |
1 (4.0) |
Naive |
1 (4.0) |
MEDD (mg/day), mean ± SD (range) |
135.4 ± 118.9 (0-500) |
Heart disease, n (%) |
8 (32.0) |
Concomitant medications (including duplicate answers), n (%) |
Acetaminophen |
8 (32.0) |
NSAIDs |
Loxoprofen |
7 (28.0) |
Celecoxib |
5 (20.0) |
Diclofenac |
1 (4.0) |
Flurbiprofen |
1 (4.0) |
Meloxicam |
1 (4.0) |
None |
12 (48.0) |
Adjuvant analgesics |
|
Corticosteroids |
12 (48.0) |
SNRI |
3 (12.0) |
Anti-arrhythmic drugs |
2 (8.0) |
Anticonvulsants |
2 (8.0) |
None |
11 (44.0) |